Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL

✍ Scribed by Simona Soverini; Giovanni Martinelli; Sabrina Colarossi; Alessandra Gnani; Michela Rondoni; Fausto Castagnetti; Stefania Paolini; Gianantonio Rosti; Michele Baccarani

• Book ID: 117784267
• Publisher: The Lancet
• Year: 2007
• Tongue: English
• Weight: 141 KB
• Volume: 8
• Category: Article
• ISSN: 1470-2045
• DOI: 10.1016/s1470-2045(07)70078-5